Clinical Trial Results Archive

Clinical Trial Results: February 2009

February 2 Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease, According to New Study
February 2 Unigene Clinical Study Suggests Novel Treatment Regimen for Osteoporosis
February 2 Ligand Announces Phase IIb Results With DARA
February 2 Hospira's Precedex Phase IV Study Published in the Journal of the American Medical Association
February 2 Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
February 2 Newer Medication May Offer Advantages Over Agents Commonly Used For Sedation of Intensive Care Unit Patients
February 3 InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
February 3 Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
February 3 InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
February 3 Merck’s Safinamide Significantly Improved Motor Function in Patients with Advanced Parkinson’s Disease in a Phase III Pivotal Trial
February 3 Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
February 3 Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
February 3 Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
February 3 Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
February 3 Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
February 3 PhytoMedical's Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests against Human Brain Cancer
February 3 AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
February 4 Allos Therapeutics Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma
February 4 OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
February 4 Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
February 4 Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
February 4 GSK and Theravance Announce Positive Phase 2b Results for Once-daily Fluticasone Furoate in the Treatment of Asthma
February 4 Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
February 5 New Evidence of Hormone Therapy Causing Breast Cancer, Stanford Professor Says
February 5 BioDelivery Sciences Announces Initial Results of Phase 1 Clinical Study of Bioral Amphotericin B
February 5 Interim Results From the MIRACEL Study Now Reported In the Renal Anaemia Disease Knowledge Centre at EPG Online
February 5 Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
February 5 Physicians from the Burzynski Clinic Present Initial Results of Combination Gene-Targeting Therapies on Advanced Pancreatic and Liver Cancers
February 5 Minocycline/Rifampin-Impregnated Catheters Proven Clinically Effective in Preventing and Combating Potentially Fatal Bloodstream Infections in Two New Studies
February 5 HemCon Medical Technologies, Inc. Announces Promising Results from Live Nail Infection Anti-Fungal Study Technology Platform Offers Tested Solution to Fungal Care Market
February 6 Bioalliance Pharma Presents Results on a New Quinoline Family on HIV Integrase Inhibitors at the 16Th Conference on Retroviruses and Opportunistic Infections (CROI)
February 9 M. D. Anderson Study Finds Pregnancy Has No Impact on Breast Cancer Survival, Does Delay Treatment, Diagnosis
February 9 Benitec Limited (ASX:BLT) City of Hope Human HIV Trial Update
February 9 Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
February 9 Anti-HIV Gel Shows Promise in Large-Scale Study in Women
February 9 ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
February 9 MS Patients Treated with Tysabri Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
February 9 EntreMed Presents Initial Clinical Results for ENMD-2076
February 9 New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide
February 9 Winston Pharmaceuticals Announces Positive Top-line Results of Phase I Clinical Trial of Civamide Patch
February 9 Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
February 10 ConjuChem reports final data confirming PC-DAC:Exendin-4 lowers glucose and weight in Phase II diabetes trials
February 10 Starpharma Holdings Limited (ASX:SPL) Topical Microbicide Field Receives a Boost with Human Efficacy Result
February 10 Theratechnologies presents data at CROI
February 10 Phase III Studies Showed Isentress in Combination Therapy Provided Significant Viral Load Reductions Through 96 Weeks in Treatment-Experienced Patients with Triple-Class Resistant HIV
February 10 Data from Isentress, Merck's HIV Integrase Inhibitor, in Patients Whose HIV is Controlled on a Lopinavir/Ritonavir-Based Therapy Presented at the 16th Conference on Retroviruses and Opportunistic Infections
February 10 Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
February 10 Study Demonstrates Restylane Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
February 10 Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic
February 11 Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
February 11 Regenocyte Therapeutic Reports Successful Treatment of Cardiomyopathy with Stem Cells
February 11 CLSI Publishes Guideline for Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data
February 11 Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
February 11 Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder
February 12 La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial
February 12 Zometa Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
February 12 Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
February 12 Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium
February 12 New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq (dronedarone) in Atrial Fibrillation
February 12 Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
February 12 GenoMed's Results Supported by Canadian Study: Dose is Key!
February 12 Hope for 14 Million Rosacea Sufferers: Pyratine-XR Study to be Presented at South Beach Symposium
February 12 Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire
February 12 Promising medical news for atrial fibrillation patients
February 13 Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting
February 13 Study Reveals Avosentan May Slow Progression of Diabetic Kidney Disease
February 17 Update of Long-Term Data on Brain Cancer Patients Receiving DCVax-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
February 17 IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
February 17 Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
February 17 BioSante Pharmaceuticals, Inc. Presents LibiGel Clinical and Market Information at ISSWSH Conference
February 17 Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
February 17 Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease
February 17 Pluristem Therapeutics to Present at Italian CREM Workshop Focused on Placental-Derived Cells
February 17 Newly Published Menopause Study: 'Bioidentical' and FDA-Approved Divigel (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
February 17 University of Ottawa Heart Institute Scientists Unlock Mechanism That Turns on Weight-Loss Gene
February 17 Transgene Confirms Longer Survival For Patients Treated With Tg4010 In Its Ongoing Phase IIb Non-Small Cell Lung Cancer Trial
February 17 Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
February 17 Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
February 17 Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
February 18 High-Throughput Genotyping of AML Patients for a Key Immune Receptor May Significantly Improve Treatment Outcome
February 18 Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
February 18 Compared To Standard Therapies, Pixantrone Decreases Time To Achieve Complete Remission By 47% In Relapsed Aggressive Non-Hodgkin's Lymphoma
February 18 VGX Pharmaceuticals Proprietary DNA Vaccines Delivered with Electroporation Achieve Immune Responses Superior to Recombinant Adenovirus Serotype 5 (Ad5) Vectors
February 18 Phase III Results in SOFIA Study of NPL-2008
February 18 iCo Therapeutics Oral Amphotericin B Published in Leading Journal
February 18 Lancet Oncology: Epigenetic drug doubles survival in patients with 'preleukemia,' MDS
February 18 Stanford Scientists Identify Drug to Treat Opioid Addiction
February 18 Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
February 18 KanekaQH Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure
February 18 Data Published in The Lancet Oncology Further Substantiates VIDAZA's Extended Survival Benefit for MDS Patients
February 19 Research Brings New Hope to Multiple Sclerosis Patients
February 19 Kidney Disease Affects Response to Blood Thinner
February 19 New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX Trial
February 19 Crestor Cuts Risk of Stroke by Nearly Half in JUPITER Study
February 20 EPIX Pharmaceuticals to Present Preclinical Data for Two Programs at Keystone Symposia
February 20 ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
February 20 Study of Genzyme Oral Compound for Gaucher Disease Meets Primary Endpoint
February 20 UCB Announces Top-Line Outcomes for Proof-of-Concept Studies
February 23 Bavarian Nordic A/S (DK) - Bavarian Nordic updates on Phase I/II studies with breast cancer vaccine
February 23 EpiCept Announces EPC2407 Generic Name is Crinobulin
February 23 Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
February 23 Clinical Results with RegeneRx's Ophthalmic Drug Candidate Subject of Oral Presentation at 2009 ARVO Meeting
February 23 VGX Pharmaceuticals Avian Influenza DNA Vaccine Delivered with Electroporation Provides 100% Protection of Non-Human Primates
February 23 Data on VELCADE (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
February 24 AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
February 24 Orion Corporation (FI) - Orion: Primary Objective of STRIDE-PD Study Was Not Achieved
February 24 Optimer Pharmaceuticals Announces Positive Results from Second Phase 3 Study of Prulifloxacin for Infectious Diarrhea in Travelers
February 24 Tekmira Presents Data Demonstrating Further Increases in SNALP Potency
February 24 MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
February 24 PharmAthene Presents Data for SparVax and Valortim, a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
February 25 Adipose-Derived Stem and Regenerative Cells Prevent Mortality and Reduce Kidney Damage in Preclinical Study
February 25 Bavarian Nordic reports further data on Prostvac
February 25 Avigen Announces Positive Data for AV411 in Pain Relief and Drug Addiction
February 25 PharmAthene Anthrax Protection Data Presented at ASM Biodefense Disease Meeting
February 25 AVEO Pharmaceuticals' Oral, Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer
February 25 Hawaii Biotech Reports Phase 1 Results for West Nile Virus Vaccine
February 25 Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
February 25 Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
February 25 New Cancer Treatment Stops Aggressive Sarcomas
February 25 Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
February 26 CPEX Pharmaceuticals Announces Completion of Phase 2 Trial for Urology Drug by Serenity Pharmaceuticals
February 26 Optimer Pharmaceuticals Announces Publication in Peer-Reviewed Journal about Prulifloxacin's Antibacterial Activity against Infectious Diarrhea Producing Bacteria
February 26 Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
February 26 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
February 26 DeveloGen AG (DE) - DeveloGen Reports Positive Phase 1 Clinical Trial Results for DG3173
February 26 RegeneRx Updates on Phase II Venous Stasis Trial  
February 26 Crucell N.V. (NL) - Crucell's Revolutionary Antibody for Universal Therapy Against Flu
February 26 Reproductive Factors May Protect Women from Parkinson's Disease
February 26 Research Finding Could Revolutionize Asthma Treatment
February 27 Safety and Overall Survival Data in Docetaxel-Refractory Patients Enrolled in the Satraplatin SPARC Trial Being Presented at 2009 ASCO Genitourinary Cancers Symposium
February 27 BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma
February 27 Diabetes Patients With High Triglycerides and Low HDL Cholesterol get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
February 27 Safety and Overall Survival Data in Docetaxel-Refractory Patients Enrolled in the Satraplatin SPARC Trial Being Presented at 2009 ASCO Genitourinary Cancers Symposium
February 27 Mesoblast Limited (ASX:MSB) Presents Positive Adult Stem Cell Results To American Academy of Orthopedic Surgeons (AAOS)
February 27 Cell Genesys Announces Final Results from Phase 3 Program of GVAX Immunotherapy for Prostate Cancer
February 27 Cougar Biotechnology Announces Presentation of Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO 2009 Genitourinary Cancers Symposium
February 27 Data Published in The Lancet Show Fampridine-SR Improved Walking Ability in People with Multiple Sclerosis
February 27 Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
February 27 Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

Clinical Trial Results Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec

MedNotes
Advertisement

(web3)